Summary
Orchestra’s agents monitor studies, campaigns and dependencies across biopharma programmes. OpenAI said the acquisition will support agents that connect scientific findings with studies, decisions and next steps needed to advance medicines.
Why it matters
The acquisition broadens OpenAI’s life-sciences strategy from scientific reasoning toward operational coordination across the drug-development pipeline.
Related coverage
- OpenAI brings frontier models and Codex to Google Cloud
- Anthropic’s draft IPO filing reveals extraordinary future compute commitments
- SpaceX says its AI business became its largest revenue segment